Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing predominantly preclinical animal (rat) studies and mechanistic concepts
PubMed 41754849 · doi:10.3390/ph19020309
What was done
The authors reviewed preclinical and clinical literature evaluating platelet-rich plasma (PRP), growth factors (PDGF, TGF-β1, IGF-1, FGF, VEGF, BMPs), and stable gastric pentadecapeptide BPC 157 for repairing complex musculoskeletal tissue and junctional injuries (osteotendinous, myotendinous, and muscle-to-bone junctions).
What was found
The abstract reports no numerical data or effect estimates. Qualitatively, it reports that while traditional growth factors improve soft tissue healing when delivered with local carriers, several (PDGF, TGF-β1, IGF-1) show limited efficacy in muscle and junctional repair. In contrast, BPC 157 administered alone demonstrated consistent healing across tendon, ligament, muscle, and junctional injuries in rat studies across systemic (intraperitoneal, intragastric, drinking water) and local (cream) routes.
Why it matters
Musculoskeletal junction injuries are difficult to regenerate because standard growth factors rarely restore complex tissue-to-bone or muscle-to-tendon interfaces. Preclinical evidence for standalone peptides like BPC 157 outlines potential mechanisms for non-scaffold-dependent cytoprotection and tissue repair.
Limits
The abstract provides no quantitative metrics, specific search methodology, study counts, or human clinical trial results. The reported efficacy of BPC 157 relies primarily on rodent models, leaving translational safety and therapeutic efficacy in humans unproven.
Cited by
- supports In animal models, BPC-157 accelerates healing after tendon transection and ACL transection, and topically prevents gastric ulceration in burn wound models.